CG

Carol Gaddum

Executive Director, Forecasting, Analytics & New Product Planning at FibroGen

Carol Gaddum has a diverse work experience spanning various roles and industries. Carol began their career as a Trainee at Fresenius SE in 2005 and worked there until 2008. Carol then joined Deutsche Bank as an Analyst in 2010 for a brief period of six months. In 2011, Carol joined ZS as a Manager and held that position for eight years until 2019. During this time, they gained expertise in analytics and management. In 2019, they joined Portola Pharmaceuticals as a Senior Director, focusing on forecasting and analytics. After two years, they moved on to FibroGen, Inc. in 2021, where they initially served as the Senior Director of Analytics, Forecasting & Commercial Operations and later took on the role of Executive Director of Forecasting, Analytics & New Product Planning in March 2022. Carol has proven experience in forecasting, analytics, commercial operations, and new product planning in the pharmaceutical industry.

Carol Gaddum pursued their education in a chronological manner. Starting in 2005, they attended accadis Hochschule and completed their Bachelor's degree in International Business Administration by 2008. Building on this foundation, from 2008 to 2010, they undertook further studies at The London School of Economics and Political Science (LSE), obtaining a Master of Science (MSc) degree in Management.

Location

San Francisco, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


FibroGen

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.


Industries

Employees

501-1,000

Links